scholarly journals 0300 The Circadian Timing of Sleep Affects the Rate of Accumulation of Neurobehavioral Impairment Across Days of Sleep Restriction

SLEEP ◽  
2020 ◽  
Vol 43 (Supplement_1) ◽  
pp. A113-A114
Author(s):  
M E McCauley ◽  
H Van Dongen ◽  
S Banks ◽  
D F Dinges

Abstract Introduction Chronic restriction of nighttime sleep to less than ~8h/day leads to build-up of neurobehavioral impairment across days. Although it is known that sleep loss effects depend on the circadian timing of sleep, it is not known how the timing of restricted sleep influences the accumulation of neurobehavioral impairment over days. Here we studied the accumulation of impairment across days of restricted sleep placed in the morning or afternoon. Methods N=71 healthy young adults (39% female; ages 21-45y, mean±SD: 27.9±6.6y) completed a 14-day laboratory study. After two baseline days with nighttime sleep (8h TIB: 23:30-07:30), subjects were randomized to 10 consecutive days of A) morning sleep at 4h, 6h, or 8h TIB ending at 11:30 each day (n=18, 8, 8, respectively), or B) afternoon sleep at 4h, 6h, or 8h TIB ending at 19:30 each day (n=13, 17, 7, respectively). Subjects were tested on the 10min psychomotor vigilance test (PVT) every ~2 hours during scheduled wakefulness. Daily averages for PVT lapses (RTs>500ms) observed between 2h and 14h after awakening were analyzed with non-linear mixed-effects regression to investigate differences in the neurobehavioral impairment build-up rate between sleep restriction conditions. Results Afternoon sleep conditions showed a significant sleep dose-response effect (p<0.001), with the fastest accrual of PVT performance deficits across days in the 4h condition, and slow-to-negligible accumulation (p=0.36) of PVT performance deficits in the 8h condition. However, morning sleep resulted in no significant sleep dose-response effect (p=0.96). All 3 morning sleep doses displayed negligible (p≥0.12) accumulation of impairment across days. Conclusion In this sample of young adults, sleep dosages ending in the morning (at 11:30) appear to provide considerable protection against cumulative performance deficits from sleep restricted to 4h-6h/day over 10 days, suggesting that the afternoon circadian promotion of wakefulness can sustain behavioral alertness even over multiple days of repeated sleep restriction. Support NIH grants R01-NR04281 and M01-RR00040

2009 ◽  
Vol 24 (S1) ◽  
pp. 1-1
Author(s):  
B. Herman ◽  
F. Mandel

Objective:There appears to be no dose-response effect for pregabalin at doses of 300-600 mg, and a modest dose-response effect in the range of 150-300 mg. The goal of the current investigation was to determine the effect of the starting dose on the speed of onset of anxiolytic efficacy.Methods:Data were analyzed from 7 trials of outpatients with DSM-IV GAD and a HAM-A total score ≥18. Starting doses of pregabalin ranged from 100 mg (N=301) or 150 mg (N=104), to 200 mg (N=167) and 300 mg (N=388). Assessment of early improvement included the HAM-A total score and CGI-Severity and Improvement scores.Results:The mean Week 1 HAM-A change score was similar for a starting dose of 200 mg/d with no titration (-8.24) when compared to patients who started on 200 mg/d and then titrated up to 400 mg/d on Day 4 (-8.64). The mean Week 1 HAM-A change score was somewhat higher for patients started on 300 mg/d, and then titrated to 450 mg/d on Day 4/5 (-8.84) when compared to patients started on a lower (100/150 mg/d) dose and titrated on Day 5 to 400/450 mg/d (-7.32). Starting on a dose of 300 mg/d with no titration resulted in an intermediate Week 1 change score (-7.87). The interaction of starting dose and titration schedule with baseline anxiety severity will be summarized in detail.Conclusion:The initial dose of pregabalin appears to have only a weak effect on the speed of onset of anxiolytic improvement.


1990 ◽  
Vol 46 (4) ◽  
pp. 664-668 ◽  
Author(s):  
Subhkij Angsubhakorn ◽  
Panisa Get-Ngern ◽  
Makoto Miyamoto ◽  
Natth Bhamarapravati

2018 ◽  
Vol 66 (50) ◽  
pp. 13173-13182 ◽  
Author(s):  
Wei Wang ◽  
Weichun Yang ◽  
Ziyi Shen ◽  
Sixian Wen ◽  
Minyu Hu

Thorax ◽  
2018 ◽  
Vol 74 (6) ◽  
pp. 607-610 ◽  
Author(s):  
Anthony A Laverty ◽  
Filippos T Filippidis ◽  
David Taylor-Robinson ◽  
Christopher Millett ◽  
Andrew Bush ◽  
...  

We used data from 11 577 children in the UK Millennium Cohort Study, collected at approximately 14 years of age (early teens), to assess characteristics associated with smoking, and generated regional estimates of numbers of smokers. 13.8% of UK early teens studied had ever smoked; 1.9% were current smokers. This corresponds to 2 28 136 and 39 653 (13–14 year olds) in the UK, respectively. Ever smoking risk increased if caregivers (26.0% vs 10.9%) or friends smoked (35.1% vs 4.0%), with a dose–response effect for friends’ smoking. Caregiver and peer-group smoking remain important drivers of child smoking uptake and thus important targets for intervention.


2012 ◽  
Vol 26 (S1) ◽  
Author(s):  
Lynn Cialdella-Kam ◽  
David C. Nieman ◽  
Wei Sha ◽  
Mary Pat Meaney ◽  
Amy M. Knab ◽  
...  

1983 ◽  
pp. 221-230 ◽  
Author(s):  
P. Larochelle ◽  
L. Belanger ◽  
F. Lemire ◽  
D. Phaneuf ◽  
R. Huot

Circulation ◽  
2019 ◽  
Vol 139 (Suppl_1) ◽  
Author(s):  
Jennifer Fleming ◽  
Penny Kris-Etherton ◽  
Kristina Petersen ◽  
David Baer

Sign in / Sign up

Export Citation Format

Share Document